Provided by Tiger Trade Technology Pte. Ltd.

Information

6.08
+0.02000.33%
Post-market: 6.080.00000.00%16:15 EDT
Volume:217.49K
Turnover:1.32M
Market Cap:294.35M
PE:25.35
High:6.12
Open:6.05
Low:5.97
Close:6.06
52wk High:6.45
52wk Low:3.74
Shares:48.41M
Float Shares:35.55M
Volume Ratio:0.87
T/O Rate:0.61%
Dividend:0.18
Dividend Rate:2.96%
EPS(TTM):0.2399
EPS(LYR):0.1900
ROE:12.30%
ROA:6.36%
PB:3.07
PE(LYR):32.00

Loading ...

Digital Information Technologies posts steady sales growth and maintains robust shareholder returns

TIPRANKS
·
Aug 12

Digital Information Techs FY Net Y2.09b vs Net Y2.18b

Dow Jones
·
Aug 12

Visual Guide: Shanghai's 15th Five-Year Plan for Software and IT Services

Deep News
·
Aug 12

CBA Publishes Basel III Capital and Risk Disclosures for June 2026

TIPRANKS
·
Aug 12

Agriculture Department taps C3 AI to trim Salesforce use, The Information says

TIPRANKS
·
Aug 12

ISG Report Says Swiss Firms Step up AI Governance in Future-of-Work Strategies

Reuters
·
Aug 11

Lan Fa Textile Appoints Chief Information Security Officer; Shares Down 4%

MT Newswires Live
·
Aug 11

Talkweb Information System H1 Profit Down 12%, Revenue Ticks Up 0.4%

MT Newswires Live
·
Aug 10

Keymed Biosciences (SEHK:2162) Hits A Phase III Milestone, Is The Upside Already Priced In?

Simply Wall St.
·
Aug 10

Luzhu Biotech’s Herpes Zoster Vaccine LZ901 Shows Strong Phase III Results in China

TIPRANKS
·
Aug 09

Seri Industrial Publishes Merger Information Document with Related Party SE.RI.

TIPRANKS
·
Aug 09

Smartiks Yazilim AS Updates Head Office Contact Information

TIPRANKS
·
Aug 08

Fosun Pharma Launches Head-to-Head Phase 3 Clinical Trial for a First-in-Class Drug

Deep News
·
Aug 07

Alebund’s AP301 NDA Accepted in China After Strong Phase III Dialysis Data

TIPRANKS
·
Aug 07

CR Double-Crane Pharmaceutical's Unit Completes Registration of Phase III Trial of Pregabalin Tablets

MT Newswires Live
·
Aug 07

Press Release: Tetragon Financial Group Limited Dividend Information in Respect of Q2 2026

Dow Jones
·
Aug 07

Artiva Therapeutics: Buy Rating Reiterated on Strong AlloNK RA Profile and Upcoming Phase III, Price Target Maintained at $41

TIPRANKS
·
Aug 07

Table: AVer Information 2Q Net Profit Nt$65.2m vs Net Loss Nt$40.0m

Dow Jones
·
Aug 07

Toho Holdings to Absorb Information Processing Subsidiary

MT Newswires Live
·
Aug 07

Structure Therapeutics Earns Buy Rating as Lead Oral GLP‑1 Obesity Drug Enters Phase III and Pipeline, Commercial Leadership Bolster Growth Outlook

TIPRANKS
·
Aug 07